ReviewRSC advances2026
Keck asymmetric allylation in natural product synthesis: applications and developments (2018-2026).
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following our 2017 comprehensive review, this update highlights the evolving and pivotal role of the Ti-BINOL-catalyzed Keck asymmetric allylation in modern total synthesis. Highly regarded for its operational simplicity and outstanding enantiocontrol, the methodology still represents a cornerstone for the synthesis of optically active homoallylic alcohols and the assembly of complex molecular architectures. Herein, we review its application as a key stereodefining step in the recent syntheses of several structurally diverse and biologically active targets including (+)-ineleganolide, (+)-sieboldine A, ieodomycin derivatives, latrunculin B, (-)-melearoride A, PF1163B, cryptorigidifoliol G, cryptoconcatone I, and antarlides A-F. Besides traditional applications, this review also covers recent methodological advances to improve reaction efficiency, including the implementation of modified ligand frameworks and optimized additive systems. We also discuss frontier approaches that extend the classical scope of the reaction, with particular emphasis on emerging three-component asymmetric Tsuji-Trost allylations using chiral aldehydes and dual palladium catalysis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.